Wasp venom toxin MP1 blasts holes in cancer cells
4 September 2015 | By Victoria White
Research reveals exactly how the Polybia paulista wasp's venom toxin - called MP1 - selectively kills cancer cells without harming normal cells...
List view / Grid view
News
In conversation – Thoughts on the current status of the sequencing industry. An interview with Jacqueline Boultwood, University of Oxford
4 September 2015 | By Oxford Global
In the run up to our 2015 Next Generation Sequencing Congress, Single Cell Congress & Genome Editing Congress we spoke with Jacqueline Boultwood, University of Oxford, a confirmed speaker at the congress, about her thoughts on the current status of the sequencing industry...
Final agenda is now available for our 2nd Annual Drug Discovery USA Congress in Boston
4 September 2015 | By Oxford Global
Production is now complete for the 2nd Annual Drug Discovery USA Congress taking place on the 29th & 30th of October 2015 in Boston, USA...
Aspirin could boost cancer immunotherapy
4 September 2015 | By Victoria White
Researchers have shown that combining immunotherapy with aspirin or other COX inhibitors substantially slowed bowel and melanoma skin cancer growth in mice...
Another step closer to cheap synthetic antivenoms
4 September 2015 | By Victoria White
Researchers have successfully identified the exact composition of sea snake venom, which makes the future development of synthetic antivenoms more realistic...
Researchers use KG5 to sensitise tumours to radiation and chemotherapy
4 September 2015 | By Victoria White
Researchers have identified a pathway that causes resistance to chemotherapy and radiation treatments and a new drug, KG5, that targets this pathway...
Antisense RNAi therapeutics deals value approached $5.6 billion in 2014
3 September 2015 | By Victoria White
The deals market for antisense RNAi therapeutics witnessed a record year in 2014, with a total value of almost $5.6 billion across 59 transactions...
AmpliPhi appoints new VP of Chemisty, Manufacturing & Control
3 September 2015 | By Victoria White
AmpliPhi Biosciences Corporation has announced that Alexander Gaidamaka has been appointed as the new Vice President of Chemistry, Manufacturing and Control...
Breakthrough in fighting liver disease
3 September 2015 | By Victoria White
The University of Brighton has announced it is sharing in a €5.9m EU grant to support the development of a new treatment for chronic liver disease...
Horizon and Redx sign cancer research collaboration
3 September 2015 | By Victoria White
Horizon and Redx have announced a new research collaboration to progress Redx’s pan-RAF inhibitor programme, for out-licensing in oncology indications...
Genetic testing reveals new drug targets in oesophageal cancer
2 September 2015 | By Victoria White
Nearly all advanced oesophageal cancers harbour genetic mutations that can be targeted with emerging drug therapies, according to a new study...
ESCMID publishes guidelines aimed at preventing build-up of biofilms
2 September 2015 | By Victoria White
ESCMID advocates the need for greater education, guidance and research on the build-up, treatment and prevention of biofilms...
Novogen announces outcome of science review
2 September 2015 | By Victoria White
Novogen has confirmed its scientific review has identified high value opportunities for its technology platforms in areas of unmet patient need...
Positive initial clinical data from Phase 1 trial with ALN-PCSsc
2 September 2015 | By Victoria White
In the Phase 1 study, subcutaneous administration of ALN-PCSsc resulted in an up to 83% lowering of LDL-C, with an up to 64 ± 5% mean maximum reduction, comparable to published results for anti-PCSK9 MAbs...
Bristol-Myers Squibb and QIMR Berghofer Medical Research Institute announce worldwide collaboration to discover novel Immuno-Oncology Antibodies
1 September 2015 | By Charlotte Batchelor
Bristol-Myers Squibb Company and QIMR Berghofer Medical Research Institute have signed a research collaboration and license agreement to discover novel therapeutic antibodies against an undisclosed immuno-oncology...